HC Wainwright restated their buy rating on shares of Kazia Therapeutics (NASDAQ:KZIA – Free Report) in a report issued on Friday, Benzinga reports. HC Wainwright currently has a $2.00 price target on the stock.
Kazia Therapeutics Stock Down 37.7 %
KZIA stock opened at $0.56 on Friday. Kazia Therapeutics has a 12 month low of $0.19 and a 12 month high of $1.58. The firm’s 50-day moving average is $0.30 and its 200 day moving average is $0.31.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Kazia Therapeutics stock. Platinum Investment Management Ltd. purchased a new position in Kazia Therapeutics Limited (NASDAQ:KZIA – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,821,887 shares of the company’s stock, valued at approximately $801,000. Platinum Investment Management Ltd. owned 11.15% of Kazia Therapeutics at the end of the most recent reporting period. Institutional investors own 30.89% of the company’s stock.
Kazia Therapeutics Company Profile
Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.
Read More
- Five stocks we like better than Kazia Therapeutics
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Automaker’s Bold Move to an EV Future: Is It Time to Buy Stock?
- Following Congress Stock Trades
- Massive Breakout: This ETF Signals Big Gains for Small-Cap Stocks
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Major Gaming Stock to Watch: Why It’s a Safe Bet Now
Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.